Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs. Opdam MAA, Broeder ND, van den Bemt BJF, Mulder K, et al. Clin Rheumatol 2024;43:2133-2138.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Opdam MAA, Broeder ND, van den Bemt BJF, Mulder K, et al. Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs. Clin Rheumatol 2024;43:2133-2138.
PMID: 38703283